Paid Clinical Trials South Dakota
Discover 354 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05111574
Conditions
Anal Melanoma
Bladder Melanoma
Cervical Melanoma
Esophageal Melanoma
Gallbladder Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT03662126
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
Best Available Therapy (BAT)
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Sponsor:
AstraZeneca
Location:
Code:
NCT06268873
Conditions
Chronic Kidney Disease and Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baxdrostat/dapagliflozin
Dapagliflozin in combination with placebo
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Sponsor:
NRG Oncology
Location:
Code:
NCT05080673
Conditions
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Eligibility Criteria
Sex: All
Age: 50 - 70
Healthy Volunteers: Not accepted
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Comparing Two Methods to Follow Patients With Pancreatic Cysts
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04239573
Conditions
Pancreatic Carcinoma
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
Computed Tomography
Endoscopic Ultrasound
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint
Sponsor:
InGeneron, Inc.
Location:
Code:
NCT03513731
Conditions
Osteoarthritis of Facet Joint of Lumbar Spine
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Adipose-derived stem cell injection
Corticosteroid injection
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Sponsor:
Fujifilm Pharmaceuticals U.S.A., Inc.
Location:
Code:
NCT05318573
Conditions
Advanced Urothelial Carcinoma
Advanced Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
FF-10832